Incyte Corp (NASDAQ:INCY)
| 88.68 Delayed Data As of 4:00pm ET |  -0.65 / -0.73%Today’s Change | 62.48 Today|||52-Week Range 110.37 | +1.56% Year-to-Date |
Latest INCY News | Press Releases
| Tests, Treatments, Vaccines: Sorrento Therapeutics Is All In on COVID-19 Oct 19 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 89.33 |
| Today’s open | 92.36 |
| Day’s range | 87.82 - 89.75 |
| Volume | 15,987 |
| Average volume (3 months) | 1,242,957 |
| Market cap | $19.8B |
Data as of 4:00pm ET, 10/21/2020
Growth & Valuation
| Earnings growth (last year) | +299.90% |
| Earnings growth (this year) | -143.33% |
| Earnings growth (next 5 years) | +31.98% |
| Revenue growth (last year) | +14.71% |
| P/E ratio | NM |
| Price/Sales | 8.80 |
| Price/Book | 7.54 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ALNYAlnylam Pharmaceutic... | -4.93 | -3.49% |
| HZNPHorizon Therapeutics... | -0.13 | -0.17% |
| CTLTCatalent Inc | -0.55 | -0.59% |
| ALXNAlexion Pharmaceutic... | -5.86 | -4.72% |
Data as of 4:00pm ET, 10/21/2020
Financials
| Next reporting date | November 3, 2020 |
| EPS forecast (this quarter) | $0.52 |
| Annual revenue (last year) | $2.2B |
| Annual profit (last year) | $446.9M |
| Net profit margin | 20.70% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Wilmington, Delaware |
Forecasts
